Washington State University researchers have developed a new test that can identify drugs likely to be harmful to cats before those compounds reach a feline patient.

The announcement, reported by WSU Insider, addresses a gap practitioners know well. Cats metabolize many drugs differently from dogs and humans, and compounds cleared as safe in other species can cause serious adverse reactions in feline patients. A screening method that flags such compounds in advance changes the decision process at the exam table.

What does the test do?

The test screens drug compounds for feline toxicity risk. Its purpose is preventive: rather than discovering a harmful reaction after administration, a veterinarian or researcher could identify the danger while options still exist.

That distinction matters clinically. Cats present a known pharmacologic puzzle. Their metabolism differs from that of dogs and humans in ways that make cross-species safety assumptions unreliable. A tool built specifically for feline physiology gives prescribers information the current evidence base often lacks.

The practical effect is a changed risk calculation. Drugs that might otherwise pass on the strength of canine or human data can now be checked against feline criteria first.

Why cats need their own screening

Companion-animal medicine has long relied on extrapolated dosing and safety data. Dogs dominate the pharmacologic literature. Cats, with distinct metabolic pathways, absorb that uncertainty.

Adverse drug reactions in cats can be severe and sometimes fatal, and the practitioner typically learns of the risk only after exposure. A pre-prescription screening test moves that knowledge earlier in the clinical sequence.

For feline practice, the change is straightforward. Safety signals arrive before the drug is dispensed, not after the patient reacts.

What changes for practitioners?

The test's value depends on where it sits in the pipeline. Two applications follow from its described function.

• Clinical screening. Veterinarians could check a contemplated compound against feline toxicity criteria before prescribing it to a cat, particularly for drugs with thin feline safety data.
• Drug development. Pharmaceutical developers could screen candidate compounds for feline risk early, avoiding investment in products that would later prove dangerous to cats.

Both applications point to fewer feline adverse drug events. That outcome would reduce emergency presentations, hospital interventions and owner distress tied to reactions that current practice cannot reliably predict.

An early-stage tool

The announcement describes a research development at Washington State University. It does not state that the test is commercially available, nor does it specify a regulatory review pathway with any agency, including FDA CVM.

Practitioners should therefore treat this as an emerging capability rather than an immediate addition to the diagnostic menu. The underlying science, however, addresses a real and long-standing gap in feline medicine.

As the tool moves from the laboratory toward clinical and pharmaceutical use, cat-heavy practices stand to gain a safety check that no current protocol provides.